A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Clinicaltrials.gov ID
NCT05325866
Status
Recruiting
Study Type
Interventional, Phase 1
Sponsor
Amgen
Start Date
22 septembre 2022
Anticipated End Date
4 octobre 2024
Study Contact
About the Study
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Conditions
Solid Tumors
Inclusion/Exclusion Criteria?
Primary, Secondary, Other Outcome Measures??
Locations in Canada
Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada
About the Study
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Conditions
Solid Tumors
Interventions
DRUG:
Bemarituzumab
Locations in Canada
Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada